Patient Management

Managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

In order to optimise treatment outcomes as well as patients’ quality of life, it is important to understand immune-related adverse events (irAEs), including their:

Early recognition and prompt appropriate treatment of irAEs:1

Explore these related resources to learn more about managing your patients on KEYTRUDA

Find out more about KEYTRUDA® (pembrolizumab) in mNSCLC

Sign up to MSD emails

Get the latest product updates
Receive cancer resources
Be the first to hear about our events


  1. Daniels GA et al. Emerg Med J. 2019;36:369–377.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website